CA2214029A1 - Formulations en ampoule unidose de complexes adn/lipides - Google Patents

Formulations en ampoule unidose de complexes adn/lipides Download PDF

Info

Publication number
CA2214029A1
CA2214029A1 CA002214029A CA2214029A CA2214029A1 CA 2214029 A1 CA2214029 A1 CA 2214029A1 CA 002214029 A CA002214029 A CA 002214029A CA 2214029 A CA2214029 A CA 2214029A CA 2214029 A1 CA2214029 A1 CA 2214029A1
Authority
CA
Canada
Prior art keywords
solution
cationic lipid
plasmid dna
lipid
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214029A
Other languages
English (en)
Inventor
Magda Marquet
Diana L. Burman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214029A1 publication Critical patent/CA2214029A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations en ampoule unidose de complexes ADN plasmidique/lipides cationiques, lesquelles sont destinées à une utilisation clinique chez l'homme, et préparées selon plusieurs procédés différents, par exemple, selon un procédé comprenant les étapes consistant: (a) à stériliser en autoclave une solution de lipides cationiques, à un niveau de concentration suffisamment élevé pour empêcher principalement la dégradation des lipides au cours de cette stérilisation; (b) à diluer la solution de lipides cationiques stérilisée de l'étape (a), à un degré suffisant pour empêcher notamment l'agrégation des lipides lors de l'étape (d) ci-après; (c) à stériliser par filtrage une solution d'ADN plasmidique; (d) à ajouter la solution d'ADN plasmidique stérilisée de l'étape (c) à la solution stérilisée et diluée de lipides cationiques de l'étape (b), à un niveau de force ionique inférieur à celui de l'isotonicité, afin de former des complexes ADN/lipides; et (e) à ajuster les complexes ADN/lipides de l'étape (d) afin qu'ils soient proches de l'isotonicité.
CA002214029A 1995-04-25 1996-04-11 Formulations en ampoule unidose de complexes adn/lipides Abandoned CA2214029A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42846395A 1995-04-25 1995-04-25
US08/428,463 1995-04-25

Publications (1)

Publication Number Publication Date
CA2214029A1 true CA2214029A1 (fr) 1996-10-31

Family

ID=23699001

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214029A Abandoned CA2214029A1 (fr) 1995-04-25 1996-04-11 Formulations en ampoule unidose de complexes adn/lipides

Country Status (4)

Country Link
EP (1) EP0826063A1 (fr)
JP (1) JPH11504631A (fr)
CA (1) CA2214029A1 (fr)
WO (1) WO1996034109A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770715A (en) * 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
AU729077B2 (en) * 1996-08-26 2001-01-25 Transgene S.A. Cationic lipid-nucleic acid complexes
WO1998019709A2 (fr) * 1996-11-04 1998-05-14 Qiagen Gmbh Reactifs cationiques pour transfection
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE69931166T2 (de) * 1998-08-14 2007-02-15 Valentis Inc., Burlingame Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
PL210451B1 (pl) * 1999-06-10 2012-01-31 Merial Sas Szczepionka DNA przeciwko wirusowi nosówki psów (CDV)
DE19944262A1 (de) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmazeutische Zusammensetzung in Form eines Nukleinsäure-Lipid-Komplexes, ihre Herstellung und Verwendung in der Gentherapie
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2804028B1 (fr) * 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
MXPA05003049A (es) 2002-09-19 2005-11-17 Us Gov Health & Human Serv Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
EP1572968B1 (fr) 2002-10-29 2009-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polypeptides de lutzomyia longipalpis et methodes d'utilisation desdits polypeptides
US7354593B2 (en) 2002-12-09 2008-04-08 Merial Limited Coccidial vaccine and methods of making and using same
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
CN101365484A (zh) 2005-08-15 2009-02-11 瓦克辛公司 通过给药非复制型载体化疫苗而进行的对禽类的免疫
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
BRPI0709282B8 (pt) 2006-03-29 2021-05-25 Merial Ltd vacina contra estreptococos
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
EP2116599B1 (fr) 2006-11-24 2014-08-06 Waseda University Réactif pour l'introduction d'une protéine ou d'un gène
SI2147105T1 (sl) 2007-05-02 2013-08-30 Merial Limited DNA-plazmidi z izboljšano ekspresijo in stabilnostjo
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
EP2283035B1 (fr) 2008-05-08 2015-07-29 Merial Limited Vaccin contre la leishmaniose utilisant un immunogène salivaire de phlébotome
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
ES2600612T3 (es) 2009-05-22 2017-02-10 Merial, Inc. Plásmido libre de antibióticos
CA2785653C (fr) 2009-12-28 2018-05-01 Merial Limited Antigene recombinant du ndv, et ses utilisations
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20110236416A1 (en) 2010-03-12 2011-09-29 Jean-Christophe Audonnet Foot and mouth disease virus recombinant vaccines and uses thereof
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
EP2714722B1 (fr) 2011-05-27 2019-09-11 Boehringer Ingelheim Animal Health USA Inc. Vaccins genetiques contre les virus hendra et nipah
CA2837375C (fr) 2011-06-01 2019-07-16 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
LT2734230T (lt) 2011-07-20 2019-03-25 Merial Limited Rekombinantinė kačių leikemijos viruso vakcina, turinti optimizuotą kačių leukemijos viruso apvalkalo geną
US10166188B2 (en) 2011-08-12 2019-01-01 Merial, Inc. Method for vacuum-assisted preservation of biologics including vaccines
CN104203271B (zh) 2012-02-14 2017-08-25 梅里亚股份有限公司 表达狂犬病病毒和ox40蛋白的重组痘病毒载体及从其制造的疫苗
EP2814508B1 (fr) 2012-02-14 2017-04-12 Merial, Inc. Vaccins sous-unitaires contre le rotavirus, procedés de fabrication et leur utilisation
CA2867893C (fr) 2012-03-20 2022-09-20 Merial Limited Vaccin contre l'herpesvirus equin 1 recombinant contenant une glycoproteine c mutee et utilisations associees
WO2013143555A1 (fr) 2012-03-26 2013-10-03 Biontech Ag Formulation d'arn pour immunothérapie
RU2656187C2 (ru) 2012-06-13 2018-05-31 Мериал, Инк. Реассортантные btv и ahsv вакцины
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
NZ741421A (en) 2014-05-14 2023-05-26 Vitamfero S A Methods for freeze-drying and rehydrating biologics
BR112017027895A2 (pt) 2015-06-23 2018-11-06 Merial Inc vetores virais recombinantes contendo proteínas menores de prrsv e métodos de fabricação e utilização destes
US10617752B2 (en) 2015-06-26 2020-04-14 Boehringer Ingelheim Animal Health USA Inc. Inactivated canine influenza vaccines and methods of making and uses thereof
EP4286002A3 (fr) 2015-09-29 2024-02-28 Boehringer Ingelheim Animal Health USA Inc. Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
DK3380119T3 (da) 2015-11-23 2021-11-15 Boehringer Ingelheim Animal Health Usa Inc Fmdv- og e2-fusionsproteiner og anvendelser deraf
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
AU2019258679A1 (en) * 2018-04-25 2020-10-15 Ethris Gmbh Cryoprotective agents for particulate formulations
JP7271026B1 (ja) * 2021-12-28 2023-05-11 株式会社Hyperion Drug Discovery 遺伝子導入細胞の免疫応答を回避させるための剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003808A1 (fr) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Traitement thermique de liposomes
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)

Also Published As

Publication number Publication date
WO1996034109A1 (fr) 1996-10-31
EP0826063A1 (fr) 1998-03-04
JPH11504631A (ja) 1999-04-27

Similar Documents

Publication Publication Date Title
CA2214029A1 (fr) Formulations en ampoule unidose de complexes adn/lipides
DE69725878T2 (de) Zusammensetzungen zur polynukleotidabgabe
US8771728B2 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) Stable lipid-comprising drug delivery complexes and methods for their production
US7070807B2 (en) Branched histidine copolymers and methods for using same
EP0795015B1 (fr) Plasmides appropries a l'expression de l'il-2
US7163695B2 (en) Histidine copolymer and methods for using same
US20050025821A1 (en) Lipid-comprising drug delivery complexes and methods for their production
JP2001508815A (ja) カチオン性ポリマー／脂質核酸送達ビヒクル
CA2340416C (fr) Formulation protegee, dans un seul flacon, pour molecules d'acide nucleique, ses procedes de fabrication par melangeage en ligne, produits et procedes associes
JP2001526181A (ja) 遺伝子輸送体であるグラフト共重合体
WO1998017814A2 (fr) Expression de genes, systemes d'apport et utilisations
JPWO2005054486A1 (ja) 遺伝子導入試薬調製法
EP4311559A1 (fr) Nanoparticules et peptides pour l'administration de cargos aux chondrocytes
JP2001502736A (ja) キトサン含有組成物
JP2003531181A (ja) 核酸を細胞に投与するための粒状複合体
AU2003238331B2 (en) Delivery system for pharmaceutical agents
AU8724001A (en) Gene expression and delivery systems and uses

Legal Events

Date Code Title Description
FZDE Dead